Bruker (NASDAQ:BRKR) Upgraded at Zacks Research

Zacks Research upgraded shares of Bruker (NASDAQ:BRKR) from a strong sell rating to a hold rating in a research note released on Monday,Zacks.com reports.

BRKR has been the subject of several other reports. Cowen reiterated a “hold” rating on shares of Bruker in a report on Tuesday, November 4th. UBS Group raised their price objective on shares of Bruker from $40.00 to $43.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d)” rating on shares of Bruker in a research report on Monday, December 1st. Barclays increased their target price on Bruker from $40.00 to $45.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Finally, Rothschild & Co Redburn assumed coverage on Bruker in a report on Thursday, November 20th. They set a “buy” rating and a $60.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $50.62.

Bruker Stock Performance

Shares of NASDAQ BRKR opened at $46.92 on Monday. The stock’s fifty day simple moving average is $41.28 and its 200 day simple moving average is $38.19. The stock has a market capitalization of $7.13 billion, a price-to-earnings ratio of -293.25, a PEG ratio of 6.68 and a beta of 1.17. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.81. Bruker has a 52-week low of $28.53 and a 52-week high of $64.64.

Bruker (NASDAQ:BRKR) last announced its earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.33 by $0.12. The business had revenue of $860.50 million during the quarter, compared to the consensus estimate of $847.40 million. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.Bruker’s revenue was down .5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, sell-side analysts forecast that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 2nd. Stockholders of record on Monday, December 8th will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, December 8th. Bruker’s payout ratio is currently -125.00%.

Insiders Place Their Bets

In related news, Director John A. Ornell sold 6,233 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the completion of the sale, the director directly owned 35,212 shares in the company, valued at approximately $1,373,268. This trade represents a 15.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the sale, the director directly owned 18,016 shares of the company’s stock, valued at approximately $581,016. The trade was a 16.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 27.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

Several large investors have recently made changes to their positions in the company. US Bancorp DE raised its position in Bruker by 4.1% during the first quarter. US Bancorp DE now owns 12,313 shares of the medical research company’s stock valued at $514,000 after acquiring an additional 480 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Bruker by 5.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 926,790 shares of the medical research company’s stock worth $38,684,000 after purchasing an additional 50,537 shares during the last quarter. Chicago Partners Investment Group LLC bought a new position in shares of Bruker during the 1st quarter valued at $238,000. National Bank of Canada FI lifted its stake in shares of Bruker by 20.9% in the 1st quarter. National Bank of Canada FI now owns 53,521 shares of the medical research company’s stock valued at $2,234,000 after purchasing an additional 9,240 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in Bruker in the first quarter worth $420,000. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.